Be The Match Foundation’s Triumph: Over $327,000 Raised at the Annual Los Angeles Soirée
In a remarkable display of philanthropy and community spirit, the Be The Match Foundation® celebrated its annual Los Angeles Soirée on August 11 at the Skirball Cultural Center. This event, dedicated to supporting patients battling life-threatening blood cancers and disorders, witnessed an astounding collection of over $327,000 in a single night. A Night of Hope […]
AvenCell’s AVC-201: A New Era in Leukemia Therapy
AvenCell Therapeutics, a leading clinical-stage cell therapy company, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) for AVC-201. AVC-201 is a novel allogeneic CD123-directed switchable CAR-T investigational therapy for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and other CD123 positive hematological malignancies. This therapy is the world’s […]
Revolutionary Stem Cell Breakthrough Battles Gastroesophageal Cancer
The DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI), has awarded $300,000 to Dr. Saar Gill of the University of Pennsylvania. This award is in recognition of the progress he has made in less than a year on his grant, which is in addition to the $250,000 […]
Revolution in Cancer Treatment: LIfT’s iPSCs Breakthrough
LIfT BioSciences, a rapidly emerging biotech company, has announced a significant breakthrough in cancer cell therapies. The company has successfully demonstrated proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). This development marks a new era of affordable and effective cancer cell therapies. The company’s second-generation platform, iN-LIfT, derived from […]
Stem Cells Reveal Your Breats Cancer’s Future: Discover AccuStem’s Innovative Approach
AccuStem Sciences, Inc., a clinical stage diagnostics company with a focus on enhancing outcomes for cancer patients, has unveiled a strategic plan to advance and implement the StemPrintER assay. The StemPrintER test is a 20-gene assay that classifies early-stage breast cancer patients based on their risk of recurrence. This assay measures the “stemness” of tumors, […]
Revolution in Oncology: How Stem Cell Transplants are Changing the Game in Cancer Treatment
Welcome, dear reader! It’s a pleasure to have you here as we embark on an enlightening journey into the world of stem cell transplants in oncology. This article is designed for those who are keen to learn more about cancer treatment options or are simply intrigued by the latest advancements in medical science. Consider this […]
How These College Interns Are Saving Lives and Breaking Records with Be The Match
Be The Match, the organization behind the world’s most diverse registry of blood stem cell and marrow donors, announced that the William G. Pomeroy Foundation has granted them an additional $300,000. This generous contribution will allow the organization to further diversify the Be The Match Registry by expanding its presence at historically Black colleges and […]
Be The Match Advocates Garner $420,000+ at 2023 NY Gala for Life-Saving Blood Stem Cell Transplants
On May 4, 2023, Be The Match Foundation® hosted its annual New York Gala at the Cipriani on Broadway to raise funding for patient assistance grants, research to improve transplant outcomes, and diversification of the Be The Match Registry®. In 2022, the foundation provided $6.1 million in grants to 2,320 patients and families in need […]
Unite to Fight Blood Cancer: The Vital Role of Ethnic Minority Stem Cell Donors
In this video, Antoinette, a mother of two suffering from incurable blood cancer, shares her struggle to find a stem cell donor for nine years. She has undergone eight different types of chemotherapy, and her myeloma has spread to her spine, causing 13 spinal fractures. While a stem cell transplant won’t cure her, it would […]
Innovative Cell Therapy, Omisirge, Receives FDA Approval to Reduce Infection Risk in Blood Cancer Treatments
The FDA has approved Omisirge (omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to speed up the recovery of neutrophils and reduce infection risk. Omisirge is intended for use in adults and pediatric patients aged 12 and older with blood cancers who are undergoing umbilical cord blood transplantation after a myeloablative conditioning regimen. Blood […]